Enterprise Therapeutics, a Brighton, Sussex, UK-based drug discovery company focused on new therapeutics for respiratory diseases, secured £1.6m (approximately $2.4m) in Series A financing.
Epidarex Capital made the investment.
The company intends to use the funds to for low molecular weight drug discovery and new target identification programs.
Led by Martin Gosling, CSO, Enterprise Therapeutics focuses on the discovery of novel disease modifying medications that target key drivers of disease pathology and progression including the underlying mechanisms of mucus congestion.
Enterprise’s lead indication will be cystic fibrosis, the most common lethal genetic disease amongst Caucasians with an estimated global patient population of 100,000. The average life expectancy, although improving, is approximately 40 years.
The company will be based at the University of Sussex.